BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22846865)

  • 1. Molecular targeted therapies in hepatocellular carcinoma.
    Tanaka S; Arii S
    Semin Oncol; 2012 Aug; 39(4):486-92. PubMed ID: 22846865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular changes in hepatocellular carcinoma.
    Yang ZF; Poon RT
    Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy.
    Lu LC; Shao YY; Chan SY; Hsu CH; Cheng AL
    Anticancer Res; 2014 Feb; 34(2):1047-52. PubMed ID: 24511053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy of hepatocellular carcinoma: present and future.
    Chan SL; Yeo W
    J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
    Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
    Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives.
    Zhu AX
    Semin Oncol; 2012 Aug; 39(4):493-502. PubMed ID: 22846866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypoxia in hepatocellular carcinoma].
    Myung SJ; Yoon JH
    Korean J Hepatol; 2007 Mar; 13(1):9-19. PubMed ID: 17380070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies.
    Tanaka S; Arii S
    J Gastroenterol; 2011 Mar; 46(3):289-96. PubMed ID: 21350811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatocellular carcinoma].
    Kondo S; Ueno H; Morizane C; Okusaka T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic strategies in hepatocellular carcinoma: current status.
    Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.
    Tanaka S; Arii S
    Int J Clin Oncol; 2010 Jun; 15(3):235-41. PubMed ID: 20505971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic therapy for HCC.
    Dufour JF
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):81-6. PubMed ID: 22419006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
    Kudo M
    Dig Dis; 2011; 29(3):273-7. PubMed ID: 21829017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
    Gamstätter T; Weinmann A; Schadmand-Fischer S; Spies PR; Niederle IM; Schuchmann M; Galle PR; Wörns MA
    Onkologie; 2011; 34(10):538-42. PubMed ID: 21985853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H
    Biochem Pharmacol; 2010 Sep; 80(5):550-60. PubMed ID: 20371362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis in hepatocellular carcinoma: a potential target for chemoprevention and therapy.
    Bishayee A; Darvesh AS
    Curr Cancer Drug Targets; 2012 Nov; 12(9):1095-118. PubMed ID: 22873221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
    Wu XZ
    Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.